Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IndexRUT P/E- EPS (ttm)-0.77 Insider Own8.49% Shs Outstand96.34M Perf Week-11.41%
Market Cap957.82M Forward P/E20.61 EPS next Y0.48 Insider Trans0.00% Shs Float88.18M Perf Month-33.95%
Income-72.58M PEG- EPS next Q-0.03 Inst Own74.87% Short Float10.00% Perf Quarter-32.47%
Sales138.16M P/S6.93 EPS this Y75.72% Inst Trans0.84% Short Ratio7.81 Perf Half Y-35.71%
Book/sh0.78 P/B12.83 EPS next Y199.31% ROA-40.17% Short Interest8.81M Perf Year-20.67%
Cash/sh0.68 P/C14.55 EPS next 5Y15.00% ROE-78.54% 52W Range10.41 - 19.09 Perf YTD-29.60%
Dividend Est.- P/FCF- EPS past 5Y4.78% ROI-65.79% 52W High-47.93% Beta1.30
Dividend TTM- Quick Ratio2.60 Sales past 5Y-40.99% Gross Margin93.38% 52W Low-4.51% ATR (14)0.83
Dividend Ex-Date- Current Ratio2.97 EPS Y/Y TTM64.19% Oper. Margin-46.33% RSI (14)32.28 Volatility7.03% 6.96%
Employees154 Debt/Eq0.49 Sales Y/Y TTM1523.50% Profit Margin-52.53% Recom1.00 Target Price23.64
Option/ShortYes / Yes LT Debt/Eq0.48 EPS Q/Q93.27% Payout- Rel Volume3.77 Prev Close11.59
Sales Surprise3.28% EPS Surprise63.28% Sales Q/Q613.22% EarningsNov 12 BMO Avg Volume1.13M Price9.94
SMA20-19.67% SMA50-22.92% SMA200-33.92% Trades Volume4,253,967 Change-14.24%
Date Action Analyst Rating Change Price Target Change
Jun-12-24Initiated Rodman & Renshaw Buy $27
Mar-05-24Reiterated Oppenheimer Outperform $27 → $29
Mar-05-24Reiterated Needham Buy $20 → $22
Mar-05-24Reiterated H.C. Wainwright Buy $21 → $25
Feb-06-24Initiated UBS Buy $21
Nov-30-22Upgrade Jefferies Hold → Buy $6.50 → $11
Aug-10-22Downgrade Jefferies Buy → Hold $6 → $8
Jul-28-22Resumed Craig Hallum Buy $15.50 → $12
May-26-22Downgrade Stifel Buy → Hold $9 → $2
Sep-23-21Initiated Needham Buy $17
Nov-13-24 08:00AM
02:09AM
Nov-12-24 07:21AM
07:00AM
Nov-11-24 07:10AM
08:00AM Loading…
Nov-04-24 08:00AM
Nov-01-24 11:41AM
Oct-31-24 07:00AM
Oct-24-24 08:00AM
Oct-18-24 04:34PM
Oct-17-24 09:41AM
Oct-09-24 05:36PM
Sep-25-24 08:00AM
Sep-03-24 08:00AM
Aug-28-24 08:00AM
08:46PM Loading…
Aug-27-24 08:46PM
Aug-20-24 08:00AM
Aug-08-24 07:13AM
07:00AM
Aug-06-24 04:06PM
Aug-05-24 09:55AM
Aug-01-24 08:00AM
06:32AM
Jul-31-24 04:05PM
Jun-27-24 04:05PM
May-30-24 08:00AM
May-22-24 08:00AM
May-21-24 07:00AM
May-09-24 03:36PM
May-08-24 11:55AM
09:36AM Loading…
09:36AM
08:36AM
07:17AM
07:00AM
May-01-24 08:00AM
Apr-29-24 09:55AM
Apr-21-24 10:39AM
Apr-01-24 08:00AM
Mar-05-24 10:25AM
08:00AM
Mar-04-24 03:37PM
06:30AM
Feb-26-24 08:00AM
Feb-07-24 08:00AM
Jan-18-24 10:35AM
Jan-15-24 12:00PM
09:55AM
Jan-12-24 08:32AM
Jan-08-24 07:00AM
Nov-10-23 12:16PM
Nov-08-23 07:07AM
07:00AM
Nov-07-23 08:00AM
Oct-30-23 08:00AM
Oct-20-23 08:00AM
Oct-05-23 08:00AM
Sep-26-23 11:52AM
Aug-31-23 10:16PM
08:00AM
Aug-13-23 08:09AM
Aug-11-23 08:28AM
07:01AM
Aug-10-23 10:32PM
Aug-09-23 07:07AM
07:00AM
Aug-03-23 04:05PM
Aug-02-23 08:00AM
Jul-28-23 02:56PM
Jul-20-23 04:05PM
Jul-06-23 04:05PM
Jul-03-23 04:50PM
Jun-23-23 09:57AM
Jun-22-23 08:00AM
Jun-20-23 10:10AM
Jun-14-23 08:00AM
Jun-13-23 08:00AM
Jun-06-23 04:05PM
Jun-05-23 07:00AM
Jun-01-23 08:00AM
May-31-23 04:00PM
May-21-23 08:20AM
May-05-23 03:44PM
May-04-23 06:14PM
04:05PM
May-03-23 04:05PM
07:24AM
May-01-23 01:20PM
Apr-20-23 04:05PM
Apr-10-23 08:00AM
Apr-05-23 07:44PM
Apr-03-23 04:05PM
Mar-30-23 07:00AM
Mar-29-23 09:27PM
09:24PM
04:13PM
04:01PM
Mar-22-23 07:00AM
Mar-21-23 04:05PM
Mar-02-23 07:00AM
Feb-28-23 10:37AM
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCHUGH THOMAS SChief Financial OfficerJan 16 '24Buy14.502,00029,00080,500Jan 16 04:36 PM
McCamish Mark AnthonyDirectorDec 28 '23Sale14.5375,0001,089,75067,025Dec 29 04:15 PM